AIM Vaccine Co., Ltd. Class H (HK:6660) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AIM Vaccine Co., Ltd. has announced the successful completion of Phase III clinical trials for its innovative serum-free rabies vaccine, showing promising immunogenicity and safety, meeting pre-defined clinical objectives. The vaccine is anticipated to be the first serum-free rabies vaccine in the global market, potentially reducing adverse reactions. With the construction of production facilities meeting international standards, the company is preparing to submit for marketing registration, positioning itself as a leader in rabies vaccine safety and quality.
For further insights into HK:6660 stock, check out TipRanks’ Stock Analysis page.